ScripKymera Therapeutics delivered a big win with first-in-human data for an oral STAT6 degrader, a potential new class of medicine for allergic diseases. STAT6 is a key signaling node on the IL-4/IL-13 pa
ScripWhen clinical trial details are teased but deferred, investors will take a steer from the company management and key opinion leader commentaries. This has the potential for bias. Recent events around
ScripSanofi’s immunology pipeline has suffered a couple of high-profile setbacks recently so the proposed acquisition of Blueprint Medicines Corp and Ayvakit, its already-approved therapy for advanced sy
ScripSanofi is cementing its position as an immunology powerhouse by agreeing to acquire Blueprint Medicines Corp of the US and its soon-to-be blockbuster Ayvakit in a deal that could be worth up to $9.5bn